I Gede Purna Weisnawa

I Gede Purna Weisnawa

Auto-generated profile, based on publicly available information

I Gede Purna Weisnawa

Medical faculty of udayana university

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
IWI Gede Purna Weisnawa
I Gede Purna Weisnawa
NSNi Made Susilawathi
Ni Made Susilawathi
CPCokorda Agung Wahyu Purnamasidhi
Cokorda Agung Wahyu Purnamasidhi
GPGiovanca Verentzia Purnama
Giovanca Verentzia Purnama
IAI Komang Hotra Adiputra
I Komang Hotra Adiputra
PWPutu Kintan Wulandari
Putu Kintan Wulandari
Recently, a respiratory infectious disease labeled as COVID-19 caused by SARS-CoV-2 had taken over the world by storm. This RNA virus can cause various symptoms such as malaise, anosmia, ageusia, fever, cough, headache, myalgia, diarrhea, and ARDS. COVID-19 patients have specific symptoms such as fever. In another study, it was said that anosmia could be a benchmark for screening for COVID-19. in a study of young patients and was more common in women. The average onset of anosmia occurs on day 4 after infection and lasts for 8 days. the evidence says that this disease can cause a decrease in a person's quality of life. The exact cause of anosmia is still unknown, but several theories suggest that anosmia can occur due to damage to nerve receptors, inflammation of olfactory epithelial cells, and dysfunction of nerve receptors. The popular theory is that anosmia occurs due to inflammation of the olfactory epithelial cells, thereby damaging the olfactory receptors. The inflammation blocks odors from reaching the nasal mucosa and can inhibit receptor excitability and signal transduction. Anosmia may be associated with lower hospital mortality rates. However, further research and discovery is needed to fully grasp the pathophysiological concept of COVID-19 induced anosmia. This review will discuss the pathophysiology and review the lower anosmia mortality rate. This article reviews current understandings about the pathophysiology of anosmia and its potential as a marker towards better clinical prognosis. This narrative review aims to provide knowledge about updates regarding the pathophysiology of anosmia as a clinical predictor of mild and severe COVID-19 symptoms.

14 November 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
ISI Wayan Sumardika
I Wayan Sumardika
CPCokorda Agung Wahyu Purnamasidhi
Cokorda Agung Wahyu Purnamasidhi
ADAgus Eka Darwinata
Agus Eka Darwinata
GPGiovanca Verentzia Purnama
Giovanca Verentzia Purnama
JJJerry Jerry
Jerry Jerry
IWI Gede Purna Weisnawa
I Gede Purna Weisnawa
An unknown pneumonia-like disease has emerged in Wuhan, China, in late 2019. It is later named as SARS-CoV-2 which cause COVID-19. This virus spreads easily due to high mobilization and its transmission through droplets or aerosol and fomite. The World Health Organization (WHO) then declared this disease as a global outbreak in March 2020. As the world faces the outbreak of SARS-CoV-2, many researchers race to find the most efficacious treatment for COVID-19. Until now, the most common treatments for COVID-19 were only symptomatic such as decongestant, corticosteroid, interleukin inhibitor, and existing antiviral. The researchers then develop a brand new antiviral that works efficiently to inhibit SARS-CoV-2 and might become prophylaxis. This disease is called Molnupiravir or EIDD-2801, a nucleotide analog which inhibits SARS-CoV-2 replication, resulting in damaged mRNA and lethal virions. Molnupiravir works to produce mutagenesis in RNA viruses and prevent the virus from spreading widely throughout the human body. However, this drug is still needed to undergo clinical trial phase three. In this article, we will discuss how Molnupiravir works and its efficacy compared to existing drugs. This review article aims to provide an update about novel efficacious antiviral for COVID-19, Molnupiravir.

30 November 2024 in WMJ (Warmadewa Medical Journal)
Verified
Journal Article
Open access
PDF file
GPGiovanca Verentzia Purnama
Giovanca Verentzia Purnama
CPCokorda Agung Wahyu Purnamasidhi
Cokorda Agung Wahyu Purnamasidhi
SHSaktivi Harkitasari
Saktivi Harkitasari
IAI Komang Hotra Adiputra
I Komang Hotra Adiputra
RSRichard Christian Suteja
Richard Christian Suteja
DSDewa Ayu Fony Prema Shanti
Dewa Ayu Fony Prema Shanti
Due to repetitive exposure to COVID-19 patients, healthcare workers are always at a high risk of contracting COVID-19. Hence, a study of the COVID-19 profile among healthcare workers might minimize morbidity and mortality. We conducted a cross-sectional study using medical records of healthcare workers positive for COVID-19 treated at Udayana University Hospital from April to June 2020. We excluded the medical records with missing data. Afterward, we characterized the age, symptoms, gender, comorbidities, and other variables written on the existing medical records.Patients admitted mainly were at their peak age (33.75 ± 12.241 years old) and were primarily male (62.5%). Three main professions were a doctor (58.3%), nurse (28.2%), and laboratory analyst (8.3%). The mean interval between the onset of symptoms and testing was 3.54 days, with varied lengths of stay, at most about two weeks (18.67 ± 10.357 days). Most health workers experience symptoms such as fever (66.7%), cough (58.3%), sore throat (25%), chest tightness (25%), and cold (20.8%). Only hypertension (12.5%) and DM (8.3%) were comorbidities identified. Immense exposure to the virus does increase the risk of contracting COVID-19. However, fast recognition leads to more rapid diagnosis and treatment, preventing abundant virus replication and substantially shortening the isolation period (18.67 ± 10.357 days). With only relatively young healthcare workers stationed, severe conditions requiring ventilator use were seldom seen. Constant exposure to a highly contaminated environment with insufficient protection, exacerbated by the escalated number of COVID-19 patients, negatively impacted healthcare workers. Regular testing and testing as soon as symptoms appear can shorten the length of stay and reduce the risk of COVID-19 progressing to severe symptoms.

30 June 2023 in International Journal of Medical Students
Verified
Journal Article
Open access
PDF file
RSRichard Christian Suteja
Richard Christian Suteja
IAI Komang Hotra Adiputra
I Komang Hotra Adiputra
CPCokorda Agung Wahyu Purnamasidhi
Cokorda Agung Wahyu Purnamasidhi
KHKadek Diana Harmayani
Kadek Diana Harmayani
NSNi Made Susilawathi
Ni Made Susilawathi
DSDewa Ayu Fony Prema Shanti
Dewa Ayu Fony Prema Shanti
Impacting the community does not always mean creating exponential growth, it can also mean bringing small and sustainable changes to improve people’s quality of life. Living in a developing country, we had a first-hand experience of seeing life in underprivileged communities. This experience expanded our desire to serve communities around us. However, due to the emergence of COVID-19 in Indonesia, most of the plans to contribute to our community were halted. Strict outbreak control measures, which restricted people’s mobility, prohibited visits to these underprivileged communities.

8 April 2023 in Indonesian Journal of Tropical and Infectious Disease
Verified
Journal Article
Open access
PDF file
CPCokorda Agung Wahyu Purnamasidhi
Cokorda Agung Wahyu Purnamasidhi
ISI Ketut Agus Somia
I Ketut Agus Somia
DJDarren Junior
Darren Junior
RSRichard Christian Suteja
Richard Christian Suteja
IAI Komang Hotra Adiputra
I Komang Hotra Adiputra
IDI Gusti Ngurah Ariestha Satya Diksha
I Gusti Ngurah Ariestha Satya Diksha
Elderly COVID-19 patients have been associated with worse outcomes and have been presented with the highest mortality rate. However, studies on the clinical features and the differences between critical and non-critical elderly COVID-19 patients in Indonesia and even other countries are still lacking and rare. In this retrospective study, the epidemiological and clinical features of critical and non-critical elderly COVID-19 patients admitted to Udayana University Academic Hospital between April 2020 and March 2021 were analyzed and then compared. Of the 280 medical records analyzed, 60.7% were male and the median age was 65.0 years old. Based on the medical records, 18.2% of elderly patients met our criteria of critical patients. The most common symptoms presented in both category upon admission included fever and coughing. The most common comorbidity found in critical patients was heart disease and hypertension in non-critical patients. Laboratory results differences included leukocytes, neutrophils, lymphocytes, Neutrophil-to-Lymphocyte Ratio, platelets, SGOT, SGPT, and urea. Only 9.9% of critical patients and 6.1% of non-critical patients were given antiviral therapy. In contrast, 68.6% of critical patients and 76% of non-critical patients were given antibiotics. The mortality rate in critical patients was 70.6% and 0.4% in non-critical patients. Based on the results, a multimodal approach in the treatment of elderly COVID-19 patients is very essential. The higher mortality rate in elderly patients should be able to be reduced by giving early and timely antiviral therapy with the addition of effective choice of drugs.